Clinical trials
Relapsed or Refractory Multiple Myeloma clinical trials
Below are recruiting relapsed or refractory multiple myeloma clinical trials, each written for real people, not researchers. We’re tracking 1,270 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06125405RecruitingPhase 3
Telitacicept for children with frequently relapsing nephrotic syndrome
This trial tests a new drug called telitacicept to help children whose nephrotic syndrome keeps coming back often or who need steroids to stay in remission. The goal is to see if it can keep urine protein levels low and reduce relapses.
Hangzhou, ZhejiangAges 2–18 - NCT06124287Recruiting
Can MRI predict Crohn's relapse after stopping biologics?
This study looks at whether MRI scans can predict when Crohn's disease will come back after stopping biologic medications. If you are in remission and recently stopped a biologic, researchers want to see if your MRI results can help understand your risk of relapse.
LondonAges 16 years+ - NCT06112639Recruiting
Dance-based rehab for chronic brain conditions
This trial tests a dance exercise program for people with multiple sclerosis or early memory loss. It aims to see if dancing can help physical and mental function safely at home.
BresciaAges 18–85 - NCT06105853Recruiting
Stress and brain activity in alcohol use disorder
This study looks at how people with alcohol use disorder respond to stress and what happens in the brain. You'll use a smartphone and may have an MRI scan to understand your stress responses.
Mannheim, Baden-WurttembergAges 18–65 - NCT06086197RecruitingPhase 2
A drug combo for early relapsed or refractory DLBCL
This trial tests a combination of chemotherapy drugs for people with a type of lymphoma called diffuse large B-cell lymphoma that has either come back early or never fully responded to first treatment. The goal is to see if this drug combination can help control the lymphoma.
Hangzhou, ZhejiangAges 18 years+ - NCT06079788RecruitingPhase 3
ACTH for children with frequently relapsing nephrotic syndrome
This trial tests if a hormone called ACTH can help children with nephrotic syndrome who have frequent relapses or need steroids to stay in remission. It aims to find a treatment that may reduce the need for steroids and prevent relapses.
Wuhan, HubeiAges 2–14 - NCT06062693Recruiting
Home Hand Training with Sensors for Better Dexterity
This study tests a new home-based hand training system using sensors to help improve hand movement and dexterity in people with Parkinson's, multiple sclerosis, or stroke. It also includes healthy volunteers for comparison.
LucerneAges 18–99 - NCT06017518Recruiting
Watching local relapse after high-grade osteosarcoma treatment
This study is watching people whose high-grade osteosarcoma came back in the same bone area (local relapse) after treatment. It helps doctors understand how local relapse happens, so they can improve future care.
Bologna, BOAges Any age - NCT05849857RecruitingPhase 2
Mosunetuzumab for follicular lymphoma that came back quickly
This Phase 2 study tests mosunetuzumab, an antibody treatment, for people with follicular lymphoma that relapsed (came back) or progressed soon after first treatment. It may help shrink the cancer again after early relapse or lack of response to standard therapy.
HelsinkiAges 18 years+ - NCT05861505RecruitingPhase 3
Treatment for new liver spread from colon cancer recurrence
This Phase 3 trial studies a treatment approach for people whose colorectal cancer has come back in the liver within 12 months and can be treated with local procedures. It aims to see whether the study treatment can improve outcomes compared with standard care for people with a limited number of liver tumors.
AmsterdamAges 18 years+ - NCT05833763RecruitingPhase 2
Glosfitamab plus pirtobrutinib for mantle cell lymphoma after BTK drugs
This Phase 2 trial tests how well two anti-cancer medicines—glofitamab and pirtobrutinib—work for mantle cell lymphoma (MCL) that has not responded well to prior BTK inhibitor therapy. It may help by shrinking the lymphoma after earlier treatment and checking how safe the combination is for people with similar disease history.
Parkville, VictoriaAges 18 years+ - NCT05786768RecruitingPhase 2/Phase 3
Obinutuzumab vs rituximab for relapsing childhood kidney syndrome
This study compares two antibody medicines, obinutuzumab and rituximab, to prevent relapses of steroid-dependent or frequently relapsing nephrotic syndrome in children. It looks at whether one option works better and is safer, including infection risk.
ParisAges 3–18 - NCT05772559Recruiting
Study of AML genes and drug response in young patients
This trial looks at how childhood, teen, and young adult acute myeloid leukemia (AML) changes at the genetic level and how cells respond to multiple drugs. It may help doctors understand which treatments work best and how leukemia interacts with supportive cells in the bone marrow.
AmiensAges Up to 25 years - NCT05732974Recruiting
Using a computer tool to find lung cancer relapse risk
This study uses a machine-learning computer method to identify people with early-stage lung cancer who have a higher risk of the cancer coming back after surgery. If you qualify, your information may help researchers improve how doctors predict relapse and plan follow-up care.
ToulouseAges 18 years+ - NCT05682131RecruitingPhase 4
Study for children with certain relapsed leukemia
This trial looks at treatment for children whose leukemia has come back for the first time. It focuses on a specific type of leukemia and risk level to see whether the approach improves outcomes.
Guangzhou, GuangdongAges 1–14 - NCT05704621RecruitingPhase 2
Surgery after PARP inhibitor failure in returning ovarian cancer
This trial tests whether doing additional (“secondary”) tumor-removal surgery can help people with ovarian, fallopian tube, or primary peritoneal cancer that has returned after PARP inhibitor maintenance. It focuses on people whose cancer can likely be fully removed and who are considered good candidates for surgery and follow-up treatment.
SeoulAges 18 years+ - NCT07570407Recruiting
Blood Immune Cells After Bone Marrow Transplant for Leukemia
This study measures certain immune cells in your blood after a stem cell transplant for acute myeloid leukemia (AML). It aims to understand how well your immune system recovers and may help predict how you'll do after transplant.
Pilsen, CzechiaAges 18–70 - NCT07851636Recruiting
Fast genetic testing to guide treatment for rare brain tumors
This trial tests a new way to pick treatments for rare brain tumors that have come back. Doctors will quickly analyze your tumor's genes and test drugs in the lab to find the best option for you.
Washington D.C., District of ColumbiaAges Up to 45 years - NCT07604311RecruitingPhase 4
Preventing IgA nephropathy flare-ups with Nefecon
This study tests whether continuing Nefecon after initial treatment helps prevent IgA nephropathy (a kidney disease) from coming back. If you have already been on Nefecon for at least 9 months and your protein levels are low now, you might be able to join.
Guangzhou, GuangdongAges 18–75 - NCT07852156Recruiting
Cooling during inpatient rehabilitation for people with multiple sclerosis
This trial tests whether cooling the body during a stay at a rehabilitation clinic helps people with multiple sclerosis (MS) feel better and recover more effectively. If you have MS and find that heat makes your symptoms worse, this study may help you manage your symptoms during rehab.
Valens, Canton of St. GallenAges 18 years+ - NCT07753928Enrolling by invitation
Tracking brain changes in multiple sclerosis
This study looks at how certain brain changes relate to disability in people with multiple sclerosis (MS). It aims to see if measuring brain volume loss can help predict disease progression, which might help tailor treatments.
DresdenAges 18–55 - NCT07673354Enrolling by invitation
Spinal cord stimulation at home for hand and arm function in MS
This trial tests if gentle electrical stimulation can help improve hand and arm function in people with multiple sclerosis. You will use a small device at home with support from a caregiver.
Seattle, WashingtonAges 18–70
Hear when a new Relapsed or Refractory Multiple Myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for relapsed or refractory multiple myeloma?
- Yes. Clin2 currently lists 1,270 recruiting relapsed or refractory multiple myeloma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a relapsed or refractory multiple myeloma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a relapsed or refractory multiple myeloma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.